{"id":873653,"date":"2025-08-09T07:46:07","date_gmt":"2025-08-09T11:46:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/"},"modified":"2025-08-09T07:46:07","modified_gmt":"2025-08-09T11:46:07","slug":"rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/","title":{"rendered":"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST)"},"content":{"rendered":"
\n

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP<\/strong><\/a> announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws.<\/p>\n

If you invested in RxSight, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases-investigations\/rxsight-inc-class-action-lawsuit<\/strong><\/a>.<\/p>\n

Investors have until September 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Makaveev v. RxSight, Inc., et al.<\/em>, No. 25-cv- 01596.<\/p>\n

\n Why Was RxSight Sued for Securities Fraud? <\/strong>\n <\/p>\n

RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company\u2019s main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens\u2019s shape and power to optimize vision based on the patient\u2019s individual needs and preferences.
\u00a0
During the relevant period, the Company touted its strong LAL and LDD sales and failed to disclose \u201cadoption challenges\u201d in its products. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024.<\/p>\n

\n The Stock Declines as the Truth Is Revealed<\/strong>\n <\/p>\n

On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a \u201csoftening\u201d of the market that purportedly occurred \u201cin the second half of 2024.\u201d On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025.
\u00a0
Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to \u201cthe slower ramp in LAL utilization that was first noted\u00a0in 2024\u201d and \u201c[a]doption challenges over the last few quarters.\u201d\u00a0On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025.<\/p>\n

\n Click here for more information: <\/strong>
\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/rxsight-inc-class-action-lawsuit<\/strong>
\n <\/a>
\n .<\/strong>\n <\/p>\n

\n What Can You Do?<\/strong>\n <\/p>\n

If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm.<\/p>\n

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p>\n

\n Submit your information by visiting:<\/strong>\n <\/p>\n

\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/rxsight-inc-class-action-lawsuit<\/strong>
\n <\/a>\n <\/p>\n

Or contact:
Ross Shikowitz
ross@bfalaw.com<\/a>
212.789.3619<\/p>\n

\n Why Bleichmar Fonti & Auld LLP?<\/strong>\n <\/p>\n

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by\u00a0Chambers USA<\/em>,\u00a0The Legal 500<\/em>, and\u00a0ISS SCAS<\/em>, and its attorneys have been named \u201cElite Trial Lawyers\u201d by the\u00a0National Law Journal<\/em>, among the top \u201c500 Leading Plaintiff Financial Lawyers\u201d by\u00a0Lawdragon<\/em>, \u201cTitans of the Plaintiffs\u2019 Bar\u201d by\u00a0Law360<\/em>\u00a0and \u201cSuperLawyers\u201d by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p>\n

For more information about BFA and its attorneys, please visit https:\/\/www.bfalaw.com<\/a>.<\/p>\n

\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/rxsight-inc-class-action-lawsuit<\/strong>
\n <\/a>\n <\/p>\n

\n Attorney advertising. Past results do not guarantee future outcomes.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases-investigations\/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Makaveev v. … <\/p>\n

Continue reading “RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-873653","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases-investigations\/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Makaveev v. … Continue reading "RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-09T11:46:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST)\",\"datePublished\":\"2025-08-09T11:46:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/\"},\"wordCount\":597,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/\",\"name\":\"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=\",\"datePublished\":\"2025-08-09T11:46:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/","og_locale":"en_US","og_type":"article","og_title":"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST) - Market Newsdesk","og_description":"NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases-investigations\/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Makaveev v. … Continue reading \"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-09T11:46:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST)","datePublished":"2025-08-09T11:46:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/"},"wordCount":597,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/","name":"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=","datePublished":"2025-08-09T11:46:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU2MSM3MDg4NTkyIzIyOTA5OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rxst-news-did-rxsight-inc-mislead-investors-contact-bfa-law-by-september-22-class-action-deadline-nasdaqrxst\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/873653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=873653"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/873653\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=873653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=873653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=873653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}